secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001438533-24-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q2 FILSPARI sales $27.1M, up 37% Q/Q; 521 new patient start forms
-------------------------------------------------------------------------

- Net product sales $52.2M (incl. $27.1M FILSPARI); total revenue $54.1M.
- Net loss $70.4M ($0.91/share); adjusted net loss $50.1M ($0.65/share).
- Cash & equivalents $325.4M at June 30, 2024.
- PDUFA target date Sept 5, 2024 for FILSPARI full approval in IgAN.
- Received 521 PSFs in Q2; 2,484 total since launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000030/0001438533-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000030/tvtx-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer